Products formulated for IV administration should be used to treat myxedema coma.
Use of oral thyroid hormone is not recommended in myxedema coma. Monitor patients during concomitant administration of SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency. Patients with coronary artery disease who are receiving SYNTHROID should be monitored closely during surgical procedures for cardiac arrhythmias. If cardiac symptoms develop or worsen, the SYNTHROID dose should be reduced or withheld for one week and restarted at a lower dose. In the elderly and in patients with cardiovascular disease, SYNTHROID should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease. Titrate the dose of SYNTHROID carefully and monitor response to titration to avoid these effects. In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age. Overtreatment or undertreatment with SYNTHROID may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients. SYNTHROID has a narrow therapeutic index. SYNTHROID is contraindicated in patients with uncorrected adrenal insufficiency. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. The health-eligible plans and/or PBMs listed here have not endorsed and are not affiliated with this AbbVie material. The health plans and/or PBMs listed here have not endorsed and are not affiliated with this material. Please consult with payers directly for the most current reimbursement policies. ‡Coverage requirements and benefit designs vary by payer and may change over time. Step edits, prior authorization, and other restrictions apply. Covered is defined as patient has access and plan coverage of product at any formulary tier and product is not NDC blocked. *Formulary definitions: Access means the product is covered and not NDC blocked. #SYNTHROID COPAY CARD RESTRICTIONS FULL#
To learn about AbbVie’s privacy practices and your privacy choices, visit For full Terms and Conditions.įor eligible commercially covered patients, 86% paid no more than $25 for a 30-day prescription when a SYNTHROID co-pay card was used. For full Terms and Conditions, visit or call 1-86 for additional information. Restrictions, including monthly maximums, may apply. Offer subject to change or termination without notice. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law.
†Eligibility: Available to patients with commercial insurance coverage for SYNTHROID who meet eligibility criteria. Co-pay support is not available to all US patients.
*Based on claims processed from calendar year 2020. AbbVie does not guarantee that the use of any information provided here will result in coverage.Įligible health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this AbbVie material. This material is not intended to provide reimbursement or legal advice. Please be aware that coverage requirements vary by payer and change over time, so please consult with each payer directly for the most current coverage and reimbursement policies and determination processes.
The health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this material.ĪbbVie is committed to helping appropriate patients obtain access to SYNTHROID by providing reimbursement and access information. § Health plan blinded for contractual reasons.Ĭoverage requirement and benefit designs vary by payer and may change over time. ‡ Formulary definitions: Covered is defined as patient has access and plan coverage of product at any formulary tier and product is not NDC blocked.
0 kommentar(er)
